Israel’s Vectorious Medical Technologies developed a miniature implant for left-atrial monitoring to detect heart failure.

Israeli startup, founded in 2010, is set to launch a pivotal trial of its minimally invasive, implanted, interatrial shunt device for treating patients with severe symptomatic heart failure.

Yael Zilberman-Simakov has developed a technology for heart patients allowing them to monitor the risk of heart failure with a prick of the finger, in the same way diabetics do.

Vectorious Medical Technologies, which developed a miniature implant for left-atrial monitoring to detect heart failure, says the funding will go toward workforce expansion and clinical trials.

By 2030, almost 23.6 million people will die from cardiovascular diseases yearly, according to the World Health Organization. The Israeli company CardioFit is testing a world’s-first nerve-stimulation device which balances the autonomic nervous system of heart-failure patients.

Israeli scientists for the first time succeeded in transforming the skin cells of heart-failure patients into healthy heart-muscle cells, using stem cell therapy. The method was tested in rats, suggesting that it may be possible to repair an organ with one’s own tissue.